Physician profile
Ryan Oconnor
NPI 1609052117
$1,301.11
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $52.51 · 2021: $402 · 2022: $651.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $637.50 | 2022 | |
| Abbvie INC. | $185.03 | 2019-2021 | |
| Allergan, INC. | $135.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.31 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.34 | 2021 | |
| Nestle Healthcare Nutrition INC. | $55.20 | 2021-2022 | |
| Redhill Biopharma INC. | $33.98 | 2020-2021 | |
| Shire North American Group INC | $32.99 | 2019 | |
| Pfizer INC. | $25.64 | 2021 | |
| Janssen Biotech, INC. | $21.48 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.79 | 2021 | |
| Ucb, INC. | $14.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.